About 尼拉帕尼 API

作用机制

Niraparib works by blocking the activity of PARP enzymes, which leads to the accumulation of DNA damage and ultimately cell death in cancer cells. This mechanism of action is thought to be particularly effective in cancer cells that have deficiencies in homologous recombination DNA repair, such as those with mutations in the BRCA1 or BRCA2 genes.

Niraparib is indicated for the treatment of ovarian cancer, specifically in patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. The medication is used as a maintenance treatment and is taken orally in tablet form.

适应症

Niraparib (brand name Zejula) is a medication that is indicated for the treatment of ovarian cancer. Specifically, it is indicated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more chemotherapeutic regimens and who have a deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) tumor.

Niraparib is a poly ADP ribose polymerase (PARP) inhibitor, which works by blocking the activity of PARP enzymes in cancer cells. This leads to the accumulation of DNA damage and ultimately cell death in cancer cells. The mechanism of action is thought to be particularly effective in cancer cells that have deficiencies in homologous recombination DNA repair, such as those with mutations in the BRCA1 or BRCA2 genes.

Niraparib is taken orally in tablet form and is used as a maintenance treatment, meaning it is taken after initial treatment with chemotherapy to help prevent the cancer from returning. The medication is used in combination with other treatments, as determined by a healthcare provider.

Dr. Reddy's的专长

Dr. Reddy's总部位于印度海得拉巴，是全球领先的活性药物成分（API）供应商之一。 Dr. Reddy's的API业务是美国、欧洲、巴西、拉丁美洲、日本、中国、韩国和新兴市场的制药公司的首选合作伙伴。

Dr. Reddy's博士的API业务在过去30多年来在开发和制造复杂API（如类固醇，多肽，复杂长链分子和高效API（HPAPI /肿瘤药物））方面所建立的深厚技术优势中茁壮成长。 我们在知识产权和法规事务方面的实力可以帮助我们始终如一地达到并超越监管标准，从而为这一专业知识提供补充。 Dr. Reddy's博士 尼拉帕尼 API是研发，知识产权和监管方面广泛专业知识的结果。

帮助我们的客户率先进入市场的关键组成部分是响应式供应链。 我们通过确保所有设施都高效运行并达到最新的质量，安全和生产率标准来实现这一目标。 业务和工厂之间的强大互联可以快速响应动态的市场变化，从而避免短缺并满足需求的突然激增。